FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549	

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours nor roomanas	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kulkarni Sandeep Chidambar</u>					2. Issuer Name and Ticker or Trading Symbol Zura Bio Ltd [ZURA]						5. Ro (Che	ck all applica	able)	Person(s) to Issu	
(Last)	(Last) (First) (Middle) C/O ZURA BIO LIMITED					3. Date of Earliest Transaction (Month/Day/Year) 12/09/2024						Officer (below)	(give title	Other (s below)	pecify
1489 W. WARM SPRINGS RD. #110				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable				
(Street) HENDE			89014	_							Line	Form fil	ed by More t	Reporting Person	
(City)	(S	state)	(Zip)												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transa Date (Month/D.			е	Execution Date		Code (Instr. 5)			5. Amoun Securities Beneficia Owned Fo	s Form Illy (D) o ollowing (I) (In	orm: Direct I D) or Indirect I I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code V	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	rative Conversion Date Execution Date, Tr. crity or Exercise (Month/Day/Year) if any Co		Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Share Option (Right to Buy)	\$2.76	12/09/2024		A		117,000		(1)	12/09/2034	Class A Ordinary Shares	117,000	\$0	117,000	D	

Explanation of Responses:

1. This option vests in twelve substantially equal monthly installments over a one-year period measured from October 23, 2024; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

/s/ Kim Davis, Attorney-in-Fact 12/11/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.